Our sample set of nine CML patients are from various clinical studies with attendant information on BCR::ABL1 transcript level as per the International Scale (IS %) available after 12 months of TKI therapy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.